Main Article Content
Objective: The study aims to investigate the effects of clinicopathological characteristics and laboratory data at the time of diagnosis and of the administered treatments on survival in patients with pancreatic cancer.
Material and Methods: In this retrospective cohort study, we included the patients who presented to the Medical Oncology Outpatient Clinic of Isparta Süleyman Demirel University Medical Faculty Hospital and were diagnosed with pancreatic cancer between January 1, 2010 and December 31, 2017.
Results: A total of 124 patients were examined. The median survival time was 6.97 (%95 CI:4.663-9.270) months, and the 5-year survival rate was 8%. The survival time was shorter in patients diagnosed with adenocarcinoma (HR: 5.350), history of alcohol use (HR: 2.195), an Eastern Cooperative Oncology Group (ECOG) performance score of >2 (HR:2.763), Ca 19-9 value >400 (HR:1.790). Stages 2, 3 and 4 posed 2.034, 3.175 and 6.023 times higher risk of death than stage 1, respectively. Considering the adjuvant chemotherapy group as reference, risk of death was 1.250 times higher for those who received palliative chemotherapy and 2.314 times higher for those who did not receive chemotherapy.
Conclusion: In conclusion, history of alcohol use, Ca 19-9 level, ECOG performance status, disease stage, histopathological subtype of the disease, and whether the patient received chemotherapy or radiotherapy affect survival in patients with pancreatic cancer.
2. Cancer Tomorrow [Internet]. [cited 2019 Sep 3]. Available from: https://gco.iarc.fr/tomorrow/graphic-isotype?type=1&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0
3. Daniel D. Von Hoff. Pancreatic Cancer. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 20th ed. 2018. p. 591–5.
4. Türkyılmaz M, Hacıkamiloğlu E, Deniz EB, Boztaş G, Dündar S, Ergün AK, et al. Turkey Cancer Statistics 2015. Ankara; 2018.
5. Kumar V, Abbas AK, Aster JC. Pancreas. In: Kumar V, Abbas AK, Aster JC, editors. Robbins Basic Pathology. 10th ed. 2018. p. 679–89.
6. Aier I, Semwal R, Sharma A, Varadwaj PK. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiol [Internet]. 2019;58(November 2018):104–10. Available from: https://doi.org/10.1016/j.canep.2018.12.001
7. Ünek İT. The Prognostic Factors In Patients With Pancreatic Adenocarcinoma. Dokuz Eylül Üniversitesi; 2010.
8. ECOG Performance Status - ECOG-ACRIN [Internet]. [cited 2018 Nov 15]. Available from: https://ecog-acrin.org/resources/ecog-performance-status
9. NCCN - Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education [Internet]. [cited 2018 Nov 16]. Available from: https://www.nccn.org/
10. Sun H, Ma H, Hong G, Sun H, Wang J. Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981-2010. Sci Rep. 2014;4:1–10.
11. Chua YJ, Cunningham D. Pancreatic Cancer. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison’s Principles of Internal Medicine Türkçe. 17th ed. 2013. p. 586–8.
12. Nitschke P, Volk A, Welsch T, Hackl J, Reissfelder C, Rahbari M, et al. Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: A single-center experience with 483 patients. Ann Surg. 2017;265(6):1219–25.
13. Genkinger JM, Spiegelman D, Anderson KE, Bergkvist L, Bernstein L, Van Den Brandt PA, et al. Alcohol intake and pancreatic cancer risk: A pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18(3):765–76.
14. Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: A meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86.
15. Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer [Internet]. 2014;110(8):1943–9. Available from: http://dx.doi.org/10.1038/bjc.2014.131
16. Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, et al. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Int J Clin Oncol. 2016;21(1):118–25.
17. Malwinder S, Wan Zamaniah Bt WI, Cimmeran K, Phua VCE. Prognostic factors for survival in pancreatic cancer patients from university Malaya medical centre, Malaysia. J Heal Transl Med. 2018;21(1):6–13.
18. Laheru D. Pancreatic Cancer. In: Goldman L, Schafer AI, editors. Goldman-Cecil Medicine. 25th ed. 2016. p. 1332–4.
19. Chang, Kenneth J; Parasher, Gulshan; Christie, Catherine; Largent JHA-C. Risk of Pancreatic Adenocarcinoma Disparity between African Americans and Other Race/Ethnic Groups. Am Cancer Soc. 2005;103(2):349–57.
20. Eloubeidi MA, Desmond RA, Wilcox CM, Wilson RJ, Manchikalapati P, Fouad MM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192(3):322–9.